BPC-157 + GHK-Cu Peptide Stack
The BPC-157 and GHK-Cu peptide stack represents a synergistic combination aimed at enhancing research applications in regenerative medicine. BPC-157 is known for its potent healing and recovery properties, while GHK-Cu is recognized for its capabilities in skin and tissue repair. Together, these peptides target complementary biological pathways, potentially leading to improved outcomes in wound healing, collagen synthesis, and overall tissue regeneration. This stack is of particular interest in preclinical models, where both peptides have demonstrated significant effects on various tissue types, suggesting a multifaceted approach to enhancing cellular repair mechanisms.
Stack Overview
The BPC-157 and GHK-Cu peptide stack is designed to leverage the distinct yet complementary mechanisms of both peptides to optimize healing processes. BPC-157 has been extensively studied for its ability to promote healing across multiple tissue types, while GHK-Cu has garnered attention for its role in skin and tissue repair through its involvement in collagen production and cellular signaling. The combination of these peptides may provide a robust framework for research into regenerative therapies, particularly in areas such as sports medicine and dermatology, where enhanced healing and recovery are critical.
BPC-157 in This Stack
BPC-157, a synthetic peptide composed of 15 amino acids, is derived from a protein found in human gastric juice and has shown significant regenerative properties in numerous preclinical studies. Research indicates its effectiveness in healing various tissues, including tendons, ligaments, and nerves, although human clinical trials remain limited, with only three pilot studies conducted to date. The FDA classifies BPC-157 as Category 2, which restricts its compounding and use in clinical settings. Mechanistically, BPC-157 promotes angiogenesis and modulates inflammatory responses, acting through several pathways, including the upregulation of VEGF and nitric oxide synthesis. Its short elimination half-life and resistance to gastric degradation underscore its potential for rapid action in vivo, though further studies are needed to fully elucidate its therapeutic potential in humans.
GHK-Cu in This Stack
GHK-Cu is a naturally occurring tripeptide that plays a vital role in tissue repair and regeneration. Initially identified in the early 1970s, GHK-Cu levels in plasma decline with age, which may contribute to diminished regenerative capacity. This peptide exhibits a multifaceted mechanism of action, including the chelation of copper ions, which are essential for various enzymatic processes in the body. Studies indicate that GHK-Cu stimulates collagen and elastin synthesis, promotes angiogenesis, and modulates inflammatory responses. Its ability to activate TGF-beta signaling and enhance DNA repair mechanisms further emphasizes its potential in regenerative medicine. The extensive safety profile established through decades of cosmetic use supports the exploration of GHK-Cu in therapeutic applications, particularly in the context of aging and tissue repair.
Shop Research Peptides

GHK-Cu 50mg
50mg

BPC-157 5mg
5mg

BPC-157 10mg
10mg

Retatrutide 20mg
20mg

Retatrutide 10mg
10mg

Tesamorelin 10mg
10mg

Tirzepatide 10mg
10mg

KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
GHK-Cu in Research: Reconstitution, Stability, and Handling Guide
This guide covers the essentials of working with GHK-Cu in a research setting, from reconstitution math and solvent choice to stability and purity considerations. Learn how to handle copper peptides correctly and what to verify before starting a study.
TB-500 vs BPC-157: Evidence, Dosing, Safety Compared
This reference compares TB-500 and BPC-157 across mechanism, dosing, evidence, safety, and pharmacokinetics, highlighting the thin comparative evidence and the need for further study.
BPC-157 News: FDA Advisers Weigh Easing Restrictions on Six Peptides
FDA advisers have reportedly supported easing restrictions on six peptides, a move that could reshape the peptide research landscape. While BPC-157 and TB-500 were not explicitly named, the decision signals growing regulatory attention. Here's what researchers and industry professionals should know.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe